Company intelligence / Profile preview

Fujirebio

Ownership: Public · MRCHF
Employees: ~1000
Development stage: Commercial

Overview

Fujirebio offers a broad portfolio of commercialized IVD products. Its Lumipulse® CLEIA system and associated biomarker tests are widely used globally for oncology, neurodegeneration, infectious disease diagnosis, and routine clinical chemistry. The company pioneered the first fully automated CLEIA instrument and continues to launch new high-value biomarkers with strong clinical validation.

Therapeutic areas: OncologyNeurologyInfectious Diseases
Modalities: DeviceAntibodyProteinSmall moleculeRecombinant protein
Industry: Protein Biomarker Diagnostics

Partnerships

Collaborates with major global IVD companies for supply/development/manufacturing partnerships.

Financials

Market cap: $1.2B
Total revenue: $62.1B
Enterprise value: $16.9B

Beyond the preview

Go deeper on Fujirebio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fujirebio.

Explore the full profile